Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960–9.
Article
CAS
PubMed
Google Scholar
Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–16.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron. 2014;84(3):608–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791–800.
Article
PubMed
Google Scholar
Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. The Lancet Neurology. 2012;11(8):669–78.
Article
CAS
PubMed
Google Scholar
Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3(1):13–26.
Article
PubMed
PubMed Central
Google Scholar
Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210–7.
Article
PubMed
Google Scholar
Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(Pt 7):2020–33.
Article
PubMed
PubMed Central
Google Scholar
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
Article
CAS
PubMed
Google Scholar
Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, et al. In vivo staging of regional amyloid deposition. Neurology. 2017;89(20):2031–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert MO, Dyrba M, et al. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimers Res Ther. 2019;11(1):15.
Article
PubMed
PubMed Central
Google Scholar
Teipel SJ, Temp AGM, Levin F, Dyrba M, Grothe MJ, Alzheimer’s Disease Neuroimaging I. Association of PET-based stages of amyloid deposition with neuropathological markers of Abeta pathology. Ann Clin Transl Neurol. 2021;8(1):29–42.
Teipel SJ, Dyrba M, Chiesa PA, Sakr F, Jelistratova I, Lista S, et al. In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer’s disease. Neurobiol Aging. 2020;93:98–108.
Article
CAS
PubMed
Google Scholar
Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11(9):1050–68.
Article
PubMed
Google Scholar
Chetelat G, Murray ME. Amyloid PET scan: staging beyond reading? Neurology. 2017;89(20):2029–30.
Article
PubMed
Google Scholar
Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378–84.
Article
CAS
PubMed
Google Scholar
Jelistratova I, Teipel SJ, Grothe MJ. Longitudinal validity of PET-based staging of regional amyloid deposition. Hum Brain Mapp. 2020;41(15):4219–31.
Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41(7):1398–407.
Article
CAS
PubMed
PubMed Central
Google Scholar
Beach TG, Maarouf CL, Intorcia A, Sue LI, Serrano GE, Lu M, et al. Antemortem-postmortem correlation of florbetapir (18F) PET amyloid imaging with quantitative biochemical measures of Aβ42 but not Aβ40. J Alzheimers Dis. 2018;61(4):1509–16.
Article
CAS
PubMed
Google Scholar
Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain. 2013;136(Pt 7):2217–27.
Article
PubMed
Google Scholar
Seo SW, Ayakta N, Grinberg LT, Villeneuve S, Lehmann M, Reed B, et al. Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. Neuroimage Clin. 2017;13:130–7.
Article
PubMed
Google Scholar
Ikonomovic MD, Buckley CJ, Abrahamson EE, Kofler JK, Mathis CA, Klunk WE, et al. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-beta plaques in Alzheimer’s disease. Acta Neuropathol. 2020;140(4):463–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, et al. Amyloid burden and neural function in people at risk for Alzheimer’s disease. Neurobiol Aging. 2014;35(3):576–84.
Article
CAS
PubMed
Google Scholar
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834–40.
Article
CAS
PubMed
Google Scholar
Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959–72.
CAS
PubMed
Google Scholar
Grothe M, Heinsen H, Teipel S. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer’s disease. Neurobiol Aging. 2013;34(4):1210–20.
Article
CAS
PubMed
Google Scholar
Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95–113.
Article
PubMed
Google Scholar
Gonzalez-Escamilla G, Lange C, Teipel S, Buchert R, Grothe MJ. Alzheimer’s Disease Neuroimaging I. PETPVE12: an SPM toolbox for partial volume effects correction in brain PET - application to amyloid imaging with AV45-PET. Neuroimage. 2017;147:669–77.
Article
PubMed
Google Scholar
Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992;12(4):571–83.
Article
CAS
PubMed
Google Scholar
Teipel S, Heinsen H, Amaro E Jr, Grinberg LT, Krause B, Grothe M, et al. Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer’s disease. Neurobiol Aging. 2014;35(3):482–91.
Article
CAS
PubMed
Google Scholar
Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hanseeuw BJ, Betensky RA, Schultz AP, Papp KV, Mormino EC, Sepulcre J, et al. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017;81(4):583–96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, et al. Updated TDP-43 in Alzheimer’s disease staging scheme. Acta neuropathologica. 2016;131(4):571–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jonaitis EM, Koscik RL, Clark LR, Ma Y, Betthauser TJ, Berman SE, et al. Measuring longitudinal cognition: individual tests versus composites. Alzheimers Dement (Amst). 2019;11:74–84.
Article
PubMed
PubMed Central
Google Scholar
Levin F, Ferreira D, Lange C, Dyrba M, Westman E, Buchert R, et al. Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration. Alzheimers Res Ther. 2021;13(1):49.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247–58.
Article
CAS
PubMed
Google Scholar
Rodrigue KM, Kennedy KM, Devous MD Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78(6):387–95.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gonneaud J, Arenaza-Urquijo EM, Mezenge F, Landeau B, Gaubert M, Bejanin A, et al. Increased florbetapir binding in the temporal neocortex from age 20 to 60 years. Neurology. 2017;89(24):2438–46.
Article
CAS
PubMed
Google Scholar
Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging β-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 2019;76(11):1319–29.
Palmqvist S, Scholl M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8(1):1214.
Article
PubMed
PubMed Central
CAS
Google Scholar
Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27(23):6174–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66(12):1537–44.
Article
PubMed
Google Scholar
Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer’s disease. Brain. 2008;131(Pt 7):1845–53.
Article
CAS
PubMed
Google Scholar
Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, et al. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018;14(10):1281–92.
Article
PubMed
PubMed Central
Google Scholar
Ferreira D, Machado A, Molina Y, Nieto A, Correia R, Westman E, et al. Cognitive variability during middle-age: possible association with neurodegeneration and cognitive reserve. Front Aging Neurosci. 2017;9:188.
Article
PubMed
PubMed Central
Google Scholar
Farrell ME, Kennedy KM, Rodrigue KM, Wig G, Bischof GN, Rieck JR, et al. Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose-response relationship. JAMA Neurol. 2017;74(7):830–8.
Article
PubMed
PubMed Central
Google Scholar
Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-beta: a meta-analysis. Alzheimers Dement (Amst). 2017;6:108–21.
Article
PubMed
Google Scholar
Teipel SJ, Cavedo E, Lista S, Habert MO, Potier MC, Grothe MJ, et al. Effect of Alzheimer’s disease risk and protective factors on cognitive trajectories in subjective memory complainers: an INSIGHT-preAD study. Alzheimers Dement. 2018;14(9):1126–36.
Article
PubMed
Google Scholar
Clark LR, Berman SE, Norton D, Koscik RL, Jonaitis E, Blennow K, et al. Age-accelerated cognitive decline in asymptomatic adults with CSF beta-amyloid. Neurology. 2018;90(15):e1306–e15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Farrell ME, Chen X, Rundle MM, Chan MY, Wig GS, Park DC. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology. 2018;91(19):e1809–e21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cho SH, Shin JH, Jang H, Park S, Kim HJ, Kim SE, et al. Amyloid involvement in subcortical regions predicts cognitive decline. Eur J Nucl Med Mol Imaging. 2018;45(13):2368–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sprecher KE, Bendlin BB, Racine AM, Okonkwo OC, Christian BT, Koscik RL, et al. Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging. 2015;36(9):2568–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Koscik RL, Betthauser TJ, Jonaitis EM, Allison SL, Clark LR, Hermann BP, et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement (Amst). 2020;12(1):e12007.
PubMed
PubMed Central
Google Scholar
Lopes Alves I, Heeman F, Collij LE, Salvado G, Tolboom N, Vilor-Tejedor N, et al. Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimers Res Ther. 2021;13(1):82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rullmann M, Dukart J, Hoffmann KT, Luthardt J, Tiepolt S, Patt M, et al. Partial-volume effect correction improves quantitative analysis of 18F-florbetaben beta-amyloid PET scans. J Nucl Med. 2016;57(2):198–203.
Article
CAS
PubMed
Google Scholar
Collij LE, Heeman F, Salvado G, Ingala S, Altomare D, de Wilde A, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020;95(11):e1538–e53.
Article
CAS
PubMed
PubMed Central
Google Scholar
Charidimou A, Farid K, Tsai HH, Tsai LK, Yen RF, Baron JC. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry. 2018;89(4):410–7.
Article
PubMed
Google Scholar